A shelf registration has been filed by Cancer Genetics with the SEC for an offering of up to $100 million in common stock, warrants, preferred stock and overallotment purchase rights and units. The company intends to use the net proceeds as working capital, as well as to support its other general corporate functions.
$100M shelf registration filed by Cancer Genetics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.